Hologic Continues Spending Spree With $230M Tuck-In Acquisition Of Biotheranostics

Hologic’s recent buy-outs put it in a strengthened growth and competitive position beyond COVID.

Mergers and acquisition

Hologic, Inc. announced its second acquisition this week and plans to spend $230m for the privately held diagnostics maker BioTheranostics, Inc. to align the company’s broader corporate focus on women’s health. This follows Hologic’s $64m acquisition of SOMATEX Medical Technologies GmbH, which develops minimally invasive devices for tumor diagnostics, biopsy and interventional specialties, announced on 4 January.(Also see "Hologic Acquires Somatex Medical For $64M To Expand Breast Health Care, European Sales Presence" - Medtech Insight, 4 January, 2021.)

“Acquiring Biotheranostics enables us to jump-start our entry into a large, fast-growing oncology adjacency that fits perfectly with our broader...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Deals

More from Business